Delving into the Latest Updates on NCR-101 with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

NCR 101, NCR101

Target-

Action-

Mechanism-

Therapeutic Areas

Respiratory Diseases

Active Indication

Lung Diseases, Interstitial

Inactive Indication-

Originator Organization

Nuwacell Biotechnologies Co., Ltd.

Active Organization

Nuwacell Biotechnologies Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的： Ⅰ期：评价NCR101注射液在间质性肺病患者中单次给药（SAD）和多次给药（MAD）的安全性和耐受性，确定临床用药的安全剂量。次要目的： Ⅰ期：评价NCR101注射液在间质性肺病患者中的初步有效性，为后续临床试验方案设计提供依据。

[Translation]

Main purpose: Phase I: To evaluate the safety and tolerability of single-dose (SAD) and multiple-dose (MAD) NCR101 injection in patients with interstitial lung disease, and to determine the safe dose for clinical use. Secondary purpose: Phase I: To evaluate the preliminary efficacy of NCR101 injection in patients with interstitial lung disease, and to provide a basis for the design of subsequent clinical trial programs.

Start Date-

Sponsor / Collaborator

Nuwacell Biotechnologies Co., Ltd.

[+1]

100 Clinical Results associated with NCR-101

Login to view more data

100 Translational Medicine associated with NCR-101

Login to view more data

100 Patents (Medical) associated with NCR-101

Login to view more data

100 Deals associated with NCR-101

Login to view more data